Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
This research article has led to a Practice Changing Update on DynaMed Plus. It concludes that capecitabine adjuvant therapy may improve survival in women with HER2-negative residual invasive breast cancer after neoadjuvant chemotherapy
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Health | HER2 | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Women | Xeloda